The UK, External Quality Assurance Scheme (~~AS) for steroids is designed to alert par-Iclpants to shortfalls in performance by providmg objective information on the comparability of their results with those of others who use similar methodologies; comparability being assessed on two criteria namely bias and variation in bias (VAR). Our experience with the EQAS programme for 17-0(-hydroxyprogesterone (l7P) would suggest that, as currently organised, it is unable to achieve this objective. Accurate, precise measurement of 17P is required since values are used, not only to aid diagnosis of congenital adrenal hyperplasia (CAH) in sick neonates, but also for the 'fine tuning' of replacement therapy throughout childhood that enables young CAH patients tõ chieve o~ti.m~l growth and reproductive potential. Thus It IS Imperative that 'poor performance' is quickly and correctly identified.
Assessment of performance in the 17P scheme is particularly difficult because, to date, the number of participants is small (October 1989; n = 29). Since precision of the estimate of thẽ~a n is critically dependent on numbers of participants, the true mean of EQAS samples will have relatively high inherent uncertainty. This r~blem is exacerbated by the fact that par-tlcIP.a~ts use two distinct methodologies; some participants (n = 17) use in-house 'with-extraction' procedures whereas others use commercially available 'direct' kits.
Standards in the kit assays have apparently been recalibrated to give 'appropriate values' in clinical samples. Accordingly, kit assays give a low recovery in pools spiked with endogenous 17P. Whilst spiked samples used for recovery experiments have usually been excluded from calculation of VAR in other EQAS steroid programmes, this does not hold true for that of 17P. Due to a critical shortage of plasma from CAH patients, spiked samples are routinely included in each monthly set of samples. For samples containing only endogenous hormone there is acceptable agreement between the two methods and bias is comparatively low. With spiked samples, the two groups are sometimes totally resolved, having statistically significant differences in the All-Laboratory Trimmed Mean (ALTM) (Oct 1987, Pool H 117). This disparity in performance with spiked and unspiked samples 276 Ann Clin Biochem 1990; 27: 276 278 not only contributes to the high VAR of direct assays, but also causes a substantial shift in the ALTM when spiked samples are distributed. This shift in the ALTM in tum creates a larger VAR for the group using in-house with-extraction assays. The net result is that no participant in the scheme can demonstrate a better VAR than 14 %. Typical data (October 1989) indicate that, even though the acceptance criterion is set at 20 %, only about 50 % (15/29) of the participants had acceptable VAR.
We would certainly not advocate 'curing' the problems of high VAR, and difference between Group Laboratory Trimmed Means of direct and with-extraction assays, by abandoning circulation of spiked samples. It is inevitable that EQAS schemes for 17P will be forced to circulate spiked samples because in view of difficulties in obtaining plasma from CAH patients on the requisite scale. Quantitive recovery of added analyte has been, and always should be, accepted as a necessary quality parameter for hormone assays. It is not clear to us why manufacturers have thus-far been allowed to ignore this parameter. Until manufacturers have corrected such defects, we believe circulation of spiked samples is mandatory, not only in the 17P scheme but in all other EQAS assessments of steroid assays. This will ensure that if correction for poor specificity by recalibration of standards occurs, it is at least monitored. Such recalibration is particularly dangerous in assays designed to measure hormones in children with adrenal e~zyme defects, since the presence of abnormally high amounts of unanticipated steroids can not be prejudged.
Thus, in our opinion the use of direct assays for 17P should be discontinued until such time as the direct assays can be shown to have acceptable recovery. Restricting performance of 17P assays to centres having the expertise and willingness to perform with-extraction assays would provide an effective service, since despite inclusion of an extraction step these assays allow 'day-return' reporting of results. Having laid the foundation for more effective monitoring, appropriate steps could then be taken by EQAS organisers to ensure that participants achieve a VAR not greater than 15 %. G FREAD R F WALKER P FORD D RIAD-FAHMY Tenovus Institute for Cancer Research University College of Medicine: Heath Park, Cardiff CF4 4XX, UK
